LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.

Revenue
+9.88%
EPS
+27.4%
Free cash flow
−31.0%
Total debt
−31.2%

Quarter to September 2026, against a year earlier

90.21 0.93 −1.02%
Market cap
$5.0B
P/E
25.6×
Fwd P/E
19.8×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Revenue
393.10 390.59 362.26 360.92

+8 more quarters

Revenue Growth
9.88% 10.80% 14.33% 12.15%
Gross Profit
265.00 273.67 243.75 239.77
Operating Income
28.40 49.48 41.47 42.58
EBT
46.80 18.48 27.49 27.63
Income after Tax
34.40 108.68 23.15 30.92
Net Income Common
34.30 108.57 22.29 30.91
EPS (Diluted)
0.60 1.93 0.40 0.56
Shares (Diluted, Weighted)
57.40 56.27 55.94 54.55
Gross Margin
67.41% 70.07% 67.29% 66.43%
EBIT Margin
7.22% 12.67% 11.45% 11.80%
Net Profit Margin
8.73% 27.80% 6.15% 8.56%
EBITDA
— 72.62 61.84 63.08
EBIT
28.40 49.48 41.47 42.58

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 5 Nov 2026